[Preliminary results of postoperative adjuvant treatment with tamoxifen in colorectal cancer].
OBJECTIVE
To investigate estrogen receptor (ER) expression and the effects of anti-estrogen therapy on the prognosis of colorectal carcinoma.


METHODS
ER was measured in fresh colorectal cancer tissues by Dextran-coated charcoal (DCC) assay. The relationships between ER expression and clinicopathological parameters in colorectal cancer were analyzed. Tamoxifen was administrated postoperatively as adjuvant treatment.


RESULTS
The positive rate of ER in colorectal tumor tissues was 37.0%. The 5-year survival rates of tamoxifen group and control group were 66.7% and 72.5% respectively, and there was no significant difference between the two groups. The distant metastasis rate of Tamoxifen group was significantly lower than that of control group (3% versus 20%).


CONCLUSIONS
Some colorectal carcinomas are hormone-dependent tumors, and anti-estrogen therapy has no effect on them.
Wan
De-sen
DS
Department of Abdominal Surgery, Cancer Center of Sun Yat-sen University, Guangzhou 510060, China. wds@medmail.com.cn
Li
Li-ren
LR
Li
Guo-cai
GC
Pan
Zhi-zhong
ZZ
Zhou
Zhi-wei
ZW
Chen
Min-shan
MS
Zhang
Ya-Qi
YQ
Gui
Zhi-ning
ZN
Zhang
Huai-de
HD
D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011184:Postoperative Period; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism*; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D011960:Receptors, Estrogen; D013629:Tamoxifen